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OBJECTIVE — Upon diagnosis of type 1 diabetes, patients are usually symptomatic, and
manyhaveketoacidosis.Screeningforisletautoantibodies(IAs)hasbeenshowntodecreaseA1C
level and rate of hospitalization at diabetes onset. Metabolic tests and the presence of symptoms
were described at diabetes onset during the Diabetes Prevention Trial–Type 1 (DPT-1).
RESEARCH DESIGN AND METHODS — The DPT-1 screened relatives of patients
with type 1 diabetes for islet cell autoantiobodies (ICAs). Those with positive ICAs had intrave-
nousandoralglucosetolerancetests(IVGTTsandOGTTs)andwererandomizedintooneoftwo
prevention trials. Throughout the DPT-1 parenteral and oral insulin study, 246 people were
diagnosed with type 1 diabetes.
RESULTS — Of the 246 subjects diagnosed with diabetes, 218 had data regarding the pres-
enceofsymptoms,and138(63.3%)reportednosymptomssuggestiveofdiabetes.Eightsubjects
(3.67%)presentedwithketosis.SubjectspresentedwithameanSDA1Cof6.411.15%.At
diagnosis, 90 subjects (50.8%) had A1C in the normal range (6.2%). OGTT data at the time of
diagnosis indicate that 35.4% had a glucose result of 100 mg/dl at 0 min.
CONCLUSIONS — The majority of subjects diagnosed with type 1 diabetes through the
DPT-1wereasymptomaticatonsetandhadnormalfastingglucoseandA1Clevels.Thissuggests
thatintermittentscreening(IAfollowedbyOGTT)mayallowdiagnosisofdiabetesbeforesevere
metabolic decompensation. Screening with A1C will miss identifying many of the subjects with
newly diagnosed type 1 diabetes in this cohort.
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T
ype 1 diabetes affects 15–30 mil-
lion people worldwide and 1.4 mil-
lion people in the U.S. (1) and is
responsibleforsigniﬁcantmorbidity,pre-
mature mortality, and ﬁnancial burden
(2). Onset of disease is usually preceded
by a preclinical period that can last for
months or years. Pre-diabetes can often
be detected by the presence of autoanti-
bodies to islet antigens such as GAD65,
insulin, insulinoma-associated protein 2
(IA-2), and the recently identiﬁed ZnT8
(3). These antibodies can be highly pre-
dictive of diabetes risk in children with
(4) and without (5) a ﬁrst-degree relative
with type 1 diabetes. First-degree rela-
tivesofpatientswithtype1diabetescarry
a 10- to 20-fold higher risk for diabetes
than the general population (6).
The onset of type 1 diabetes is often
marked by the presence of symptoms in-
cluding polyuria, polydipsia, polyphagia,
weight loss, and diabetic ketoacidosis
(DKA). DKA is the leading cause of mor-
bidity and mortality in children with type
1 diabetes. Approximately 25% of newly
diagnosed cases present with DKA in the
U.S. (7). Cerebral edema complicates
0.5–1% of cases of DKA in children, and
there is a 50% risk for signiﬁcant morbid-
ity and mortality in patients with cerebral
edema.New-onsetdiabetesisariskfactor
for DKA (8). Therefore, preventing DKA
at onset may have a signiﬁcant impact on
diabetes-related mortality in childhood. A
prospective follow-up of children through
the Diabetes Autoimmunity Study in the
Young (DAISY) for islet autoantibodies
(IAs)anddiabetesshowedthatchildrenfol-
lowedinDAISYwerehospitalizedlessoften
and had milder metabolic abnormalities at
diagnosis compared with a control popula-
tion of children diagnosed in the commu-
nity (9).
TheDiabetesPreventionTrial–Type1
(DPT-1) parenteral and oral insulin trials
(10,11) screened relatives of people with
type 1 diabetes with islet cell autoanti-
bodies (ICAs). Subjects positive for these
antibodies were invited for further testing
including oral and intravenous glucose
tolerance testing (OGTT and IVGTT). If
eligible, subjects were enrolled in one of
the two prevention trials and were fol-
lowedwithserialOGTTsforthediagnosis
of type 1 diabetes. By studying those di-
agnosed with diabetes during the DPT-1,
metabolic characteristics and the pres-
enceofsymptomswereevaluatedinthose
enrolled in prevention and screening tri-
als. Previous reports have focused on a
subset of asymptomatic individuals who
were diagnosed solely by 2-h OGTT (12).
Metabolictestsandthepresenceofsymp-
tomsweredescribedintheindividualsdi-
agnosed through DPT-1 during the two
clinical trials.
RESEARCH DESIGN AND
METHODS— The DPT-1 initially
screened 103,391 relatives of patients
with type 1 diabetes for ICAs. Of these,
97,273 were eligible because they did not
have diabetes, provided an adequate
blood sample, were in the required age
range (3–45 years for ﬁrst degree-
relatives and 3–20 years for second-
degree relatives), and had a qualifying
relative. There were 3,483 individuals
who were ICA positive, and 2,423 had an
IVGTT.Atotalof771wererandomizedto
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(n  372) prevention trials.
The staging of the study conﬁrmed
ICA positivity, measured insulin autoan-
tibody (IAA) status, and assessed ﬁrst-
phase insulin response (FPIR) to IVGTT.
Glucose tolerance was assessed based
on an OGTT and the presence or ab-
sence of the protective haplotype HLA-
DQA1*0102/DQB*0602 (subjects with
thishaplotypewereexcludedfrompartic-
ipation) (10). In addition to ICA and IAA
positivity, eligibility was based on the
levelofFPIR(thesumofinsulinlevelsat1
and 3 min) for IVGTTs and glucose ab-
normalities for OGTTs.
IfthesubjectwasICApositive,hadan
FPIR less than threshold (as previously
described) on two occasions, or had im-
paired fasting plasma glucose (FPG) or
impairedglucosetoleranceasdetermined
byanOGTT,heorshewaseligibleforthe
parenteralinsulintrial.Ifnoneofthemet-
abolicabnormalitieswerepresentbutIAA
waspositive,participantswereeligiblefor
the oral insulin trial (10).
Subjects enrolled in the parenteral
and oral insulin trials were seen every 6
months for an OGTT to assess glycemic
status (10,11). Neither intervention ther-
apy showed a signiﬁcant overall effect.
Thus,participationineitherofthesestud-
ieswouldnotbeexpectedtosubstantially
alter the manner in which diabetes pre-
sented. In total, 931 people (26.7% of
ICA-positive individuals) were diagnosed
with type 1 diabetes throughout partici-
pation in DPT-1 and follow-up. Individ-
uals were diagnosed during staging (n 
512), during participation in one of the
two intervention trials (n  241), after
completion of the parenteral study (n 
17), through a follow-up questionnaire
(n  156), or as part of a high-risk fol-
low-up study (n  5). Metabolic data
were available for analysis on the 241 in-
dividuals diagnosed in the intervention
studiesandthe5individualsdiagnosedas
part of the high-risk follow-up group as-
sembled to study the affect of follow-up
over time on the presence of symptoms
andmetabolicparameters.Othersubjects
did not have available metabolic data and
are not included in this report.
Tolerance test procedures
Tolerance tests were performed after an
overnight fast and insertion of an intrave-
nous line. IGTTs were performed as de-
scribed(13).Thedoseoforalglucosewas
1.75 g/kg (maximum, 75 g of carbohy-
drate). Plasma glucose values were inter-
Figure 1—A1C at onset for those diagnosed with type 1 diabetes during the DPT-1 and the last
reported A1C for those randomized in DPT-1 but not diagnosed with type 1 diabetes. A: A1C for
those diagnosed with type 1 diabetes (n  177) compared with the last reported A1C for those
randomized into the trial but not diagnosed with type 1 diabetes (n  456). These groups were
signiﬁcantly different (P  0.0001). B: ROC analysis of those diagnosed with type 1 diabetes
compared with those randomized but not diagnosed with type 1 diabetes.
Table 1—Individuals diagnosed with type 1 diabetes during the study and as part of the
high-risk follow-up compared with individuals randomized in the DPT-1 but not diagnosed
with type 1 diabetes
Diagnosed with
type 1 diabetes
Not diagnosed with
type 1 diabetes P
n 246 453
Race (white) 224 (91.87) 407 (89.8) 0.07
Sex (male) 133 (54.07) 258 (56.9) 0.58
First-degree relative with type 1 diabetes 228 (92.68) 410 (90.5) 0.40
Age at randomization (years) 11.41  7.07 15.25  10.39 0.03*
Data are n (%) or means  SD unless otherwise indicated.
DPT-1 subjects with normal A1C levels at diabetes onset
770 DIABETES CARE, VOLUME 32, NUMBER 5, MAY 2009preted according to the guidelines of the
American Diabetes Association. An FPG
of 126 mg/dl or a glucose level of 200
mg/dl after 120 min was diagnostic for
diabetes. In asymptomatic patients, diag-
nosis was conﬁrmed by a second OGTT.
If the glucose values were not conﬁrmed
at the follow-up visit, participants contin-
ued to be followed at 6-month intervals
with additional OGTTs. Random plasma
glucose 200 mg/dl in the presence of
symptomsofdiabeteswasalsoconsidered
diagnostic of diabetes. Previous studies
reported a subset of 61 individuals who
were diagnosed solely by 2-h OGTT
throughout enrollment in the DPT-1
(12).Thisanalysisexamined241subjects
diagnosedwithdiabetesduringoneofthe
intervention trials and ﬁve diagnosed as
part of a high-risk follow-up study.
Laboratory measures
All assayswereperformedaspreviouslyde-
scribed (10). Plasma glucose was measured
by the glucose oxidase method. C-peptide
levelsweredeterminedbyradioimmunoas-
say. Measurable C-peptide was considered
0.2 ng/ml because this was the lowest
level detectable by this method. A1C was
measuredusingtheVARIANT(Bio-Rad)in-
strument. The measurable range for this in-
strument was 3.6–17.0%, with normal
levels 6.2%.
Statistical analyses
Statistical analyses were performed using
GraphPad Prism 5. Continuous variables
are reported as mean  SD unless other-
wise noted. Categorical variables are re-
ported with percent. A1C within 30 days
of diagnosis was analyzed for those diag-
nosed with type 1 diabetes. In order to
deﬁne the sensitivity and speciﬁcity of
A1C as a measurement of progression to
diabetes, analysis was performed by re-
ceiver operating characteristic (ROC)
curve. The onset of type 1 diabetes was
conﬁrmed using one of three glucose val-
ues: FPG, 2-h OGTT, or random plasma
glucose test. OGTT glucose and C-
peptide results within 2 months of diag-
nosiswereanalyzed.Areaunderthecurve
for C-peptide on OGTT was calculated.
Comparisons were made with subjects
who had not developed diabetes by study
end using the last available laboratory
tests. Continuous variables were com-
pared using Student’s t test, and categor-
ical variables were compared using the 
2
test. Differences were considered signiﬁ-
cant at P  0.05.
RESULTS
Demographic characteristics
The 246 subjects diagnosed through fol-
low-up in the study were analyzed (98 in
the oral insulin trial, 143 in the parenteral
insulin trial, and 5 during the high-risk fol-
low-up study). Of the 246 people diag-
nosed throughout the study, 167 (67.9%)
were diagnosed by an OGTT, 42 (17.1%)
were diagnosed by a random plasma
glucose test, and 29 (11.8%) were diag-
nosed by FPG. The remaining eight
(3.25%) diagnoses occurred outside of
routine study evaluation by a nonstudy
physician, and diagnostic glucose data
were not available.
Baseline characteristics of those diag-
nosed through the study (n  246) were
compared with those of individuals en-
rolled in the study who did not develop
diabetes (n  453) (Table 1). There were
no signiﬁcant differences between the two
groups for race, sex, or relationship to the
index relative with type 1 diabetes. Chil-
drendiagnosedwithdiabeteswereyounger
at randomization compared with those not
diagnosed by study end (P  0.03).
Symptoms at presentation of type 1
diabetes
Of the 246 people analyzed, 28 (11.4%)
did not have data regarding the presence
of symptoms at diagnosis. These individ-
uals were excluded from analysis of
symptoms.Fortheremainingsubjects,80
(36.70%) reported a presence of at least
one symptom (71 [32.57%] reported
polyuria, 54 [24.77%] polydipsia, and 20
[9.17%] polyphagia), and 58 (26.6%) re-
ported the presence of more than one
symptom. Weight loss was reported in 21
subjects (9.63%). DKA was reported in
eight subjects (3.67%).
Laboratory tests at diagnosis
Several laboratory results were examined
for those diagnosed during the study. Of
the 246 people diagnosed, 177 (72.0%)
had an A1C within 30 days of diagnosis,
and 158 (89.3%) of these A1C tests were
within 1 week of diagnosis. The mean
A1C was 6.41  1.15%, with 2 of 177
(1.13%) having an A1C 10%, and 90
subjects(50.8%)hadaA1Cinthenormal
range(6.2%)nearthetimeofdiagnosis.
The mean A1C of the group with normal
Figure2—OGTTC-peptideresultsat120minforthosediagnosedwithtype1diabetesduringthetrial
(n175)comparedwiththelastreportedOGTTforthosenotdiagnosedwithdiabetes(n649).For
those diagnosed with diabetes, all OGTT tests were within 50 days of diagnosis (P  0.0001).
Triolo and Associates
DIABETES CARE, VOLUME 32, NUMBER 5, MAY 2009 771A1C at onset of diabetes was 5.7% and
ranged from 4.9–6.1%. A1C at diagnosis
was normal for 53% percent of subjects
lessthan18yearsofageand39%ofthose
greater than 18 years of age. A1C at diag-
nosiswascomparedwiththelastreported
A1C of individuals randomized in the
study but not diagnosed with diabetes.
The mean A1C for this group was 5.38 
0.41%(P0.0001)comparedwiththose
diagnosed with diabetes (Fig. 1A). ROC
analysis identiﬁed an A1C of 6.05% as
achieving the optimal sensitivity (53.7%)
and speciﬁcity (96.7%) (Fig. 1B).
The onset of type 1 diabetes was con-
ﬁrmed using one of three glucose tests:
FPG, 2-h OGTT, or random plasma glu-
cose test. The mean  SD glucose value
for those diagnosed based on an FPG test
(n  29) was 209.2  84.9 mg/dl, 2-h
glucose OGTT (n  167) was 289.3 
71.3 mg/dl, and random plasma glucose
(n  42) was 406.6  200.3 mg/dl. A
glucose result 500 mg/dl was present
for 14 subjects (5.7%).
OGTTs obtained within 2 months of
diagnosis were also evaluated. The me-
dian date of this OGTT was 0 days (range
50 days before diagnosis to 50 days after
diagnosis), and 91% of samples were on
the day of diagnosis. Many subjects had
FPG results 100 mg/dl (35.4%), al-
though 2-h glucose results 200 mg/dl
are less frequent.
The mean C-peptide level at time 0
min was 1.35  1.05 ng/ml (range 0.09–
8.3) compared with 1.34  0.69 ng/ml
(0.10–4.8) in those not diagnosed with
type 1 diabetes (P  0.89). At 120 min,
themeanC-peptidelevelwas3.512.29
ng/ml (0.4–12.40) compared with
4.91  2.21 ng/ml (1.0–14.3) in those
randomized in the DPT-1 but not diag-
nosed with type 1 diabetes (P  0.0001)
(Fig. 2). At 0 min, 96.6% (169/175) of
subjects diagnosed with type 1 diabetes
had a C-peptide level of 0.2 ng/ml.
The C-peptide area under the curve
was 338.6  205.1 ng/ml at 120 min for
individualsdiagnosedwithdiabetescom-
pared with 529.3  212.1 ng/ml at120
minforsubjectsrandomizedintheDPT-1
but not diagnosed with diabetes (P 
0.0001). Mean  SE C-peptide levels are
provided in Fig. 3.
CONCLUSIONS — Although DPT-1
was unsuccessful in preventing type 1 di-
abetes, the study provided valuable infor-
mation about metabolic progression to
diabetes (14) and has set the standard for
future prevention trials. Participation in
prevention trials has the potential to ben-
eﬁt subjects with a diabetes diagnosis be-
fore the development of signiﬁcant
symptoms and DKA. Early diagnosis has
the potential to identify subjects before
the complete loss of endogenous insulin
production, with the theoretical potential
to preserve the remaining -cells through
intensive diabetes management or immu-
nologic intervention.
DKA is a potentially life-threatening
complication at the onset of type 1 diabe-
tes,becauseitaccountsfor0.15%ofmor-
tality at onset, with the majority of deaths
due to cerebral edema (15). Reported fre-
quencies of DKA at diagnosis range be-
tween 15 and 67% in Europe and North
America and may be more common in
developing countries (16,17). Consistent
with the experience in the DAISY study,
very few subjects (4%) participating in
the DPT-1 presented with ketosis at onset
of diabetes, much lower than reported
frequencies of DKA in community popu-
lations.Therefore,high-riskrelativesmay
beneﬁt from close attention or screening
in order to prevent DKA at diagnosis.
Laboratory results from DPT-1 indi-
cate that individuals diagnosed through-
out the study had a lower average A1C of
6.41% than the average A1C of 10.9% re-
ported for children diagnosed in commu-
nity groups without periodic screening,
and A1C for the DPT-1–diagnosed sub-
jects was also lower for children who re-
ported a ﬁrst-degree relative diagnosed
with type 1 diabetes outside of a research
protocol (7.2%) (9). Over 53% of chil-
dren less than 18 years of age diagnosed
through the DPT-1 had a normal A1C at
onset of type 1 diabetes. Using ROC anal-
ysis to identify the optimal A1C cutoff for
both sensitivity and speciﬁcity failed to
identify a level with an acceptable sensi-
tivity (53.7% at A1C of 6%), although
speciﬁcity was high (96.7% at A1C of
6%). These data suggest that A1C is not
an effective marker for screening for early
diagnosis of type 1 diabetes.
It is widely accepted that measure-
ment of C-peptide is an appropriate out-
come measure for type 1 diabetes trials to
preserve -cell function (18). Studies
have shown that patients diagnosed
around puberty or as adults show consis-
tent baseline and stimulated C-peptide
levels ranging from 0.9–2.7 ng/ml and
1.8–3.9 ng/ml, respectively (19). In pre-
pubertal children, however, several stud-
ies have demonstrated that average
C-peptidelevelsatdiagnosisare0.6ng/
ml,indicatingmoreextensivedestruction
Figure 3—Mean  SE OGTT C-peptide for those diagnosed with type 1 diabetes versus those
randomizedinDPT-1butnotdiagnosedwithtype1diabetes.Meanvaluesareshownat0,30,60,
90, and 120 min of 2-h OGTT within 50 days of diagnosis of type 1 diabetes for those diagnosed
and the last reported OGTT for those randomized but not diagnosed with diabetes (P  0.0001).
DPT-1 subjects with normal A1C levels at diabetes onset
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(96.6% [169/175]) of subjects followed
through the DPT-1 had C-peptide levels
0.2 ng/dl at diagnosis. It has been
shown that sustaining higher levels of C-
peptide secretion is associated with fewer
microvascular complications of diabetes
andfewerepisodesofhypoglycemia(22).
Arguments against screening for dia-
betes-related antibodies are based upon
the psychological stress that may accom-
pany the knowledge of increased diabetes
risk. The BABYDIAB study showed that
parents who receive an IA-negative result
for their child are often happy, whereas
parentsthatreceiveanIA-positiveresultare
often unhappy. However, given that the
majority of subjects receive an IA-negative
result, the effect of participation in a re-
search protocol is to reduce overall anxiety.
Most parents of IA-negative and -positive
children wish to know the diabetes risk of
their child, and both groups are glad to be
informed about their child’s status (23). In
contrast, some have suggested that until a
reliable method of preventing diabetes is
identiﬁed, screening should be reserved for
the realm of research (24).
Subjects diagnosed with type 1 diabe-
tes through the DPT-1 had few symptoms,
normal A1C, rare ketosis, and evidence for
insulin production at the time of diagnosis.
This suggests that intermittent screening
and follow-up of IA-positive subjects may
allow for early diagnosis and prevent severe
metabolic decompensation at onset and
also that screening with A1C alone may not
be adequate.
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